All In MedTech

Device Trial Radar · NCT06656364

Esprit BTK Post-Approval Study

Esprit BTK Post-Approval Study (Esprit BTK PAS)

Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

200

Actual

Start

Oct 21, 2024

Primary completion

Apr 30, 2027

Study completion May 30, 2029

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Oct 24, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.

Conditions

  • Chronic Limb-Threatening Ischemia

Interventions

  • Esprit BTK SystemDevice

    The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectivenes Endpoint(s): Freedom from clinically-driven target lesion revascularization (CD-TLR)Time frame: At 1 year
  2. Primary Safety Endpoint(s):MALE at 6 months + POD at 30 days (Major Adverse Limb Event + Peri-Operative Death)Time frame: 6 months + 30 days

Locations

39 sites in 4 countries. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdale, Arizona

  • Pima Heart and Vascular Clinical Research

    Tucson, Arizona

  • UCSF Fresno

    Fresno, California

36 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.